Abstract
Clinical development of gene therapy began over 20 years ago. Currently there are more than 320 ongoing gene therapy clinical trials that are regulated by the Office of Cellular, Tissue, and Gene Therapies (OCTGT) in the Center for Biologics Evaluation and Research of the US Food and Drug Administration (FDA). The FDA's mission is to advance the public health by helping to speed innovations that make medicines safer and more effective. The diverse gene therapy products in clinical development for a wide range of disorders offer an opportunity for the FDA to fulfill that mission.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
